News

Article

SGS Invests in New E&L Laboratory in India

SGS is investing in a new E&L lab in Navi Mumbai, India, that will provide testing services.

SGS announced on Oct. 12, 2021, that it is investing in a new extractables and leachables (E&L) testing laboratory in Navi Mumbai, India. The lab is set to open by the end of 2021 and will provide testing services for verifying product safety for pharmaceutical, biopharmaceutical, and medical device companies in Southeast Asia.

The new lab will be approximately 3000 ft.2 and will offer a broad spectrum of the latest E&L testing solutions, including:

  • gas chromatography–mass spectrometry (GC–MS) and headspace–GC/MS for the analysis of semi-volatile and volatile components
  • liquid chromatography with tandem mass spectrometry (LC–MSMS) for the quantitative analysis of trace leachable components
  • high resolution LC–MSMS to generate data that supports identification of unknown components
  • and inductively coupled plasma–MS to quantitate screening and identification of inorganics.

This laboratory in India will complement SGS's existing testing network. The company has three other E&L centers of excellence located in the United States, Germany, and China.

Source: SGS

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content